March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label ... specific responses in the nasal cavity following oral administration ...

As compared to controls, elevated nasal levels of ACE2 and TMPRSS2 were associated with a 3.6-fold increased risk of SARS-CoV-2 infection. Males were also more likely to exhibit greater ACE2 and ...

Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated ... is intended to remain in the nasal cavity for approximately 4 hours post-application.

Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong local ... PL-14 Allergy Blocker is intended to remain in the nasal cavity for ...

His overuse of the product had resulted in a condition called rebound congestion syndrome, caused by inflammation of the moist inner lining of the nasal cavity. Decongestant sprays work by ...

The team recently conducted a clinical trial testing two smell aid prototypes designed to increase airflow to the nasal cavity tissue responsible for the sense of smell. One prototype is a nasal ...

The State Key Laboratory for Emerging Infectious Diseases at the University of Hong Kong (HKU) and the InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT) have pioneered an influenza virus ...